| AVPEX | RSLAX | AVPEX / RSLAX | |
| Total Expense Ratio | 1.76 | 1.74 | 101% |
| Annual Report Gross Expense Ratio | 2.11 | 1.74 | 121% |
| Fund Existence | 12 years | 24 years | - |
| Gain YTD | -1.454 | 14.061 | -10% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 250 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 21.7M | 89B | 0% |
| Annual Yield % from dividends | 7.17 | 0.18 | 4,067% |
| Returns for 1 year | -4.84 | 13.49 | -36% |
| Returns for 3 years | 34.84 | 36.50 | 95% |
| Returns for 5 years | -0.47 | -8.15 | 6% |
| Returns for 10 years | 94.82 | 63.48 | 149% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| MPEMX | 11.26 | 0.17 | +1.53% |
| Mondrian Emerging Markets Value Equity | |||
| ACGCX | 45.36 | 0.27 | +0.60% |
| American Century Disciplined Value C | |||
| BRWTX | 29.64 | 0.17 | +0.58% |
| MFS Blended Research Growth Eq R3 | |||
| MFRJX | 61.16 | 0.25 | +0.41% |
| MFS Research R4 | |||
| STCIX | 10.41 | 0.04 | +0.39% |
| Virtus Silvant Large-Cap Growth Stk A | |||